Mohammad Kian Salajegheh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohammad Kian Salajegheh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Anthony A. Amato
Department of Neurology, Division of Neuromuscular Disease, Brigham and Women's Hospital, 75 Francis Street, and Harvard Medical School, Boston, Massachusetts 02115, USA
2 shared publicationsColin Quinn
Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania
2 shared publicationsJack L. Pinkus
Department of Neurology, Division of Neuromuscular Disease, Brigham and Women's Hospital, 75 Francis Street, and Harvard Medical School, Boston, Massachusetts 02115, USA
2 shared publicationsRemedios Nazareno
2 shared publications- Steven A. Greenberg
Department of Neurology, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115, USA
2 shared publications Chris Hahn
Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
1 shared publication
Latest Publications
- Open Access
- 5 January 2016
- Vol. 15 (1) , 46-53
Myotonic disorders: A review article
The myotonic disorders are a heterogeneous group of genetically determined diseases that are unified by the presence of myotonia, which is defined as failure of muscle relaxation after activation. The presentation of these disorders can range from asymptomatic electrical myotonia, as seen in some forms of myotonia congenita (MC), to severe disability with muscle weakness, cardiac conduction defects, and other systemic features as in myotonic dystrophy type I (DM1). In this review, we describe the clinical features and pathophysiology of the different myotonic disorders, their laboratory and electrophysiologic findings and briefly review the currently available treatments.
- 5 January 2016
- Vol. 15 (1) , 46-53
Open AccessMyotonic disorders: A review article
The myotonic disorders are a heterogeneous group of genetically determined diseases that are unified by the presence of myotonia, which is defined as failure of muscle relaxation after activation. The presentation of these disorders can range from asymptomatic electrical myotonia, as seen in some forms of myotonia congenita (MC), to severe disability with muscle weakness, cardiac conduction defects, and other systemic features as in myotonic dystrophy type I (DM1). In this review, we describe the clinical features and pathophysiology of the different myotonic disorders, their laboratory and electrophysiologic findings and briefly review the currently available treatments.
- 1 August 2015
- Published by Georg Thieme Verlag KG in Seminars in Neurology
- Vol. 35 (04) , 360-368
Myotonic Disorders and Channelopathies
Myotonic dystrophies and channelopathies are rare but important causes of muscle diseases which may present with myotonia, episodic attacks of weakness, fixed muscle weakness, and atrophy or their combination. Here, the authors provide an overview of these disorders and describe their clinical and pathophysiological features, diagnostic methods, and management.
- 1 August 2015
- Published by Georg Thieme Verlag KG in Seminars in Neurology
- Vol. 35 (04) , 360-368
Myotonic Disorders and Channelopathies
Myotonic dystrophies and channelopathies are rare but important causes of muscle diseases which may present with myotonia, episodic attacks of weakness, fixed muscle weakness, and atrophy or their combination. Here, the authors provide an overview of these disorders and describe their clinical and pathophysiological features, diagnostic methods, and management.
- 10 June 2014
- Published by Wolters Kluwer Health in Neurology
- Vol. 82 (23) , e200-4
Clinical Reasoning: A 20-year-old woman with rapidly progressive weakness
A 20-year-old healthy woman developed abdominal pain accompanied by mild frontal headaches, labile mood, vomiting, and dark urine. She underwent an extensive workup including endoscopy, abdominal CT scan, and eventually exploratory laparotomy. No abdominal cause of her symptoms was detected and she was discharged. Approximately 1 week after surgery, she developed low back pain and numbness in the buttocks and upper thighs. Within several days, her sensation was reduced in her hands and she developed generalized weakness. Her only medication was an oral contraceptive, which was started 1 month before onset of abdominal symptoms. She presented to our institution 3 weeks after symptom onset and reported diffuse weakness, most prominent in the proximal arms. She still had mild pain and numbness in the abdominal area, low back, and buttocks, but the numbness in the arms and legs had subsided. Neurologic examination revealed profound symmetric weakness in the proximal arms and moderate weakness in the proximal legs. Sensory examination demonstrated a band-like area of decreased sensation to pinprick in the lower abdomen and low back. Deep tendon reflexes were 2+ at the biceps and triceps and 3+ at the knees. Hoffmann sign was present on both sides. There were 1 to 2 beats of unsustained ankle clonus bilaterally. Plantar responses were flexor. Cranial nerve examination was normal.
- 10 June 2014
- Published by Wolters Kluwer Health in Neurology
- Vol. 82 (23) , e200-4
Clinical Reasoning: A 20-year-old woman with rapidly progressive weakness
A 20-year-old healthy woman developed abdominal pain accompanied by mild frontal headaches, labile mood, vomiting, and dark urine. She underwent an extensive workup including endoscopy, abdominal CT scan, and eventually exploratory laparotomy. No abdominal cause of her symptoms was detected and she was discharged. Approximately 1 week after surgery, she developed low back pain and numbness in the buttocks and upper thighs. Within several days, her sensation was reduced in her hands and she developed generalized weakness. Her only medication was an oral contraceptive, which was started 1 month before onset of abdominal symptoms. She presented to our institution 3 weeks after symptom onset and reported diffuse weakness, most prominent in the proximal arms. She still had mild pain and numbness in the abdominal area, low back, and buttocks, but the numbness in the arms and legs had subsided. Neurologic examination revealed profound symmetric weakness in the proximal arms and moderate weakness in the proximal legs. Sensory examination demonstrated a band-like area of decreased sensation to pinprick in the lower abdomen and low back. Deep tendon reflexes were 2+ at the biceps and triceps and 3+ at the knees. Hoffmann sign was present on both sides. There were 1 to 2 beats of unsustained ankle clonus bilaterally. Plantar responses were flexor. Cranial nerve examination was normal.
- Open Access
- 23 May 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (5) , e20266
Autoantibodies against a 43 KDa Muscle Protein in Inclusion Body Myositis
Inclusion body myositis (IBM) is a poorly understood and refractory autoimmune muscle disease. Though widely believed to have no significant humoral autoimmunity, we sought to identify novel autoantibodies with high specificity for this disease. Plasma autoantibodies from 65 people, including 25 with IBM, were analyzed by immunoblots against normal human muscle. Thirteen of 25 (52%) IBM patient samples recognized an approximately 43 kDa muscle protein. No other disease (N = 25) or healthy volunteer (N = 15) samples recognized this protein. Circulating antibodies against a 43-kDa muscle autoantigen may lead to the discovery of a novel biomarker for IBM. Its high specificity for IBM among patients with autoimmune myopathies furthermore suggests a relationship to disease pathogenesis.
- 23 May 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (5) , e20266
Open AccessAutoantibodies against a 43 KDa Muscle Protein in Inclusion Body Myositis
Inclusion body myositis (IBM) is a poorly understood and refractory autoimmune muscle disease. Though widely believed to have no significant humoral autoimmunity, we sought to identify novel autoantibodies with high specificity for this disease. Plasma autoantibodies from 65 people, including 25 with IBM, were analyzed by immunoblots against normal human muscle. Thirteen of 25 (52%) IBM patient samples recognized an approximately 43 kDa muscle protein. No other disease (N = 25) or healthy volunteer (N = 15) samples recognized this protein. Circulating antibodies against a 43-kDa muscle autoantigen may lead to the discovery of a novel biomarker for IBM. Its high specificity for IBM among patients with autoimmune myopathies furthermore suggests a relationship to disease pathogenesis.
- 22 July 2009
- Published by Wiley in Muscle & Nerve
- Vol. 40 (4) , 520-528
Nature of “Tau” immunoreactivity in normal myonuclei and inclusion body myositis
Sarcoplasmic accumulation of phosphorylated‐tau has been widely stated to occur in and contribute to the pathogenesis of muscle disease in inclusion body myositis. Twenty inflammatory myopathy and 10 normal muscle samples along with a range of other tissues were stained with anti‐“tau” antibodies (tau‐5, pS422, and SMI‐31). Myonuclear and sarcoplasmic fractions were prepared using differential solubilization and laser‐capture microdissection, and immunoblots were performed using pS422 and SMI‐31 antibodies. All three antibodies demonstrated anti‐tau immunoreactivity in myonuclei from normal and diseased muscle, but not in nuclei from other tissues. Western blots showed pS422 and SMI‐31 immunoreactivity against nuclear proteins outside the region expected for phosphorylated‐tau. Antibodies previously reported to indicate abnormal accumulation of phosphorylated‐tau in IBM myofibers react to normal myonuclei and recognize proteins other than tau. Normal myonuclei contain neurofilament H or other unidentified 200 kDa proteins with similar phosphorylated motifs accounting for SMI‐31 immunoreactivity. Muscle Nerve, 2009
- 22 July 2009
- Published by Wiley in Muscle & Nerve
- Vol. 40 (4) , 520-528
Nature of “Tau” immunoreactivity in normal myonuclei and inclusion body myositis
Sarcoplasmic accumulation of phosphorylated‐tau has been widely stated to occur in and contribute to the pathogenesis of muscle disease in inclusion body myositis. Twenty inflammatory myopathy and 10 normal muscle samples along with a range of other tissues were stained with anti‐“tau” antibodies (tau‐5, pS422, and SMI‐31). Myonuclear and sarcoplasmic fractions were prepared using differential solubilization and laser‐capture microdissection, and immunoblots were performed using pS422 and SMI‐31 antibodies. All three antibodies demonstrated anti‐tau immunoreactivity in myonuclei from normal and diseased muscle, but not in nuclei from other tissues. Western blots showed pS422 and SMI‐31 immunoreactivity against nuclear proteins outside the region expected for phosphorylated‐tau. Antibodies previously reported to indicate abnormal accumulation of phosphorylated‐tau in IBM myofibers react to normal myonuclei and recognize proteins other than tau. Normal myonuclei contain neurofilament H or other unidentified 200 kDa proteins with similar phosphorylated motifs accounting for SMI‐31 immunoreactivity. Muscle Nerve, 2009
- 16 June 2009
- Published by Wiley in Muscle & Nerve
- Vol. 40 (1) , 19-31
Sarcoplasmic redistribution of nuclear TDP‐43 in inclusion body myositis
The nucleic acid binding protein TDP‐43 was recently identified in normal myonuclei and in the sarcoplasm of inclusion body myositis (IBM) muscle. Here we found TDP‐43 sarcoplasmic immunoreactivity in 23% of IBM myofibers, while other reported IBM biomarkers were less frequent, with rimmed vacuoles in 2.8%, fluorescent Congo red material in 0.57%, SMI‐31 immunoreactivity in 0.83%, and focal R1282 beta‐amyloid immunoreactivity in 0.00% of myofibers. The presence of as little as >1% of myofibers with nonnuclear sarcoplasmic TDP‐43 was highly sensitive (91%) and specific (100%) to IBM among 50 inflammatory myopathy patient samples, although some patients with hereditary inclusion body myopathies and myofibrillar myopathy also had sarcoplasmic TDP‐43. TDP‐43 mutations were sought, and none were identified. TDP‐43 could be one of many nucleic acid binding proteins that are abnormally present in IBM sarcoplasm. They could potentially interfere with the normal function of extranuclear RNAs that maintain myofiber protein production. Muscle Nerve 40: 19–31, 2009
- 16 June 2009
- Published by Wiley in Muscle & Nerve
- Vol. 40 (1) , 19-31
Sarcoplasmic redistribution of nuclear TDP‐43 in inclusion body myositis
The nucleic acid binding protein TDP‐43 was recently identified in normal myonuclei and in the sarcoplasm of inclusion body myositis (IBM) muscle. Here we found TDP‐43 sarcoplasmic immunoreactivity in 23% of IBM myofibers, while other reported IBM biomarkers were less frequent, with rimmed vacuoles in 2.8%, fluorescent Congo red material in 0.57%, SMI‐31 immunoreactivity in 0.83%, and focal R1282 beta‐amyloid immunoreactivity in 0.00% of myofibers. The presence of as little as >1% of myofibers with nonnuclear sarcoplasmic TDP‐43 was highly sensitive (91%) and specific (100%) to IBM among 50 inflammatory myopathy patient samples, although some patients with hereditary inclusion body myopathies and myofibrillar myopathy also had sarcoplasmic TDP‐43. TDP‐43 mutations were sought, and none were identified. TDP‐43 could be one of many nucleic acid binding proteins that are abnormally present in IBM sarcoplasm. They could potentially interfere with the normal function of extranuclear RNAs that maintain myofiber protein production. Muscle Nerve 40: 19–31, 2009